Companion Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Sample Type, Product and Services, Technology, End-use, Indication), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Sample Type Segment Analysis: Tissue Samples (Largest & Fastest-Growing Segment)

In 2026, tissue samples account for a 60.19% share of the companion diagnostics market and represent both the largest and fastest-growing sample type segment, reflecting their established role in identifying molecular characteristics that help determine whether patients are likely to benefit from specific targeted therapies. Tissue-based testing enables laboratories to examine tumor cells and their surrounding biological environment, supporting the detection of genetic mutations, protein expression patterns, and other biomarkers associated with treatment response. These insights are particularly important in oncology, where therapeutic decisions may depend on the presence or absence of specific molecular targets. Tissue samples obtained through biopsies or surgical procedures can provide direct information about tumor characteristics, helping clinicians select appropriate therapies and avoid treatments that may be less effective for an individual patient. Demand is supported by the growing integration of precision medicine into clinical practice and the continued development of targeted treatments that require validated companion diagnostic tests. Improvements in tissue processing, assay sensitivity, biomarker detection, and laboratory workflows are also helping expand the clinical utility of tissue-based diagnostics. However, the segment faces practical constraints, including the invasiveness of sample collection, limited tissue availability, variations in sample quality, and the possibility that a single biopsy may not fully capture tumor heterogeneity. These challenges are encouraging continued efforts to improve testing efficiency and complement tissue analysis with alternative sample types where clinically appropriate. Despite these considerations, tissue samples remain central to companion diagnostics because of their established role in biomarker validation and treatment-selection pathways.

Product and Services Segment Analysis: Assays, Kits, and Reagents (Largest & Fastest-Growing Segment)

Assays, kits, and reagents account for a 60.87% market share in 2026 within the companion diagnostics market and represent both the largest and fastest-growing product and services segment, reflecting their direct role in detecting clinically relevant biomarkers and translating molecular findings into treatment decisions. These products provide the essential materials required to process patient samples, identify specific genetic or protein markers, and generate analytical results that guide the selection of targeted therapies. Their importance is closely linked to the expanding use of precision medicine, particularly in oncology, where treatment eligibility may depend on a validated biomarker result. Standardized diagnostic kits can support consistent testing procedures, while specialized reagents enable the detection and measurement of molecular targets using different analytical technologies. Demand for companion diagnostics is further supported by the development of new targeted therapies, which creates a need for corresponding diagnostic assays capable of identifying suitable patient populations. Advances in assay design, analytical sensitivity, workflow automation, and reagent stability are helping laboratories improve testing reliability and operational efficiency. The segment also benefits from the recurring need for consumables as diagnostic tests are performed across clinical laboratories and healthcare institutions. Nevertheless, product adoption depends on analytical performance, reproducibility, compatibility with laboratory instruments, regulatory requirements, and the availability of appropriate clinical validation. Manufacturers must also address differences in sample preparation, laboratory capabilities, and testing protocols across healthcare settings. As companion diagnostics expand into additional therapeutic areas, the ability to provide dependable, standardized, and clinically relevant assay solutions will remain a key factor supporting demand for this segment.

Technology Segment Analysis: Polymerase Chain Reaction (PCR) (Largest Segment) vs Next-generation Sequencing (NGS) (Fastest-Growing Segment)

Polymerase chain reaction (PCR) represents the largest technology segment in the companion diagnostics market, capturing a 29.88% share in 2026, due to its established use in detecting specific genetic alterations and other molecular markers relevant to treatment selection. PCR-based methods can amplify targeted genetic material, enabling sensitive detection of biomarkers even when they are present in limited quantities within a patient sample. Their clinical relevance is supported by established laboratory workflows, relatively straightforward interpretation for defined targets, and compatibility with a range of diagnostic platforms. In companion diagnostics, PCR is particularly useful when treatment decisions depend on identifying a known mutation or confirming the presence of a specific molecular feature. Its established infrastructure and familiarity among laboratory professionals also support implementation across clinical settings. Continued improvements in assay design, automation, and testing efficiency help maintain PCR's importance, although its targeted approach can limit its ability to identify a broad range of alterations simultaneously. Performance may also depend on sample quality, the specific biomarker being assessed, and the design of the diagnostic assay.

Next-generation sequencing (NGS) is the fastest-growing technology segment, capturing a rapidly expanding market share as companion diagnostics increasingly require broader molecular profiling to support complex treatment decisions. Unlike methods designed to detect a limited set of predefined targets, NGS can examine multiple genes and genetic alterations within a single testing workflow, helping identify biomarkers that may influence eligibility for targeted therapies. This broader analytical scope is particularly valuable in cancers with diverse molecular profiles, where testing for a wider range of alterations may reveal clinically relevant treatment options. NGS adoption is supported by advances in sequencing platforms, bioinformatics, sample preparation, and laboratory automation, alongside the growing availability of targeted therapies linked to specific molecular findings. Broader profiling can also reduce the need to conduct separate tests for individual biomarkers, depending on the clinical setting and testing strategy. However, implementation requires appropriate laboratory infrastructure, specialized analytical expertise, reliable interpretation of complex results, and clear procedures for managing findings with uncertain clinical significance. Turnaround time, reimbursement considerations, sample quality, and the availability of validated companion diagnostic assays can also influence adoption. As precision medicine expands and treatment decisions become more dependent on complex biomarker profiles, NGS is positioned to gain importance where comprehensive molecular analysis offers meaningful clinical value.